Tirzepatide Dosing Guide

Summary: Tirzepatide starts at 2.5 mg once weekly and steps up by 2.5 mg every four weeks to a maximum of 15 mg, with the right maintenance dose decided by glycemic or weight goal and tolerated by titrating slowly through GI side effects.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Tirzepatide is dosed once weekly by subcutaneous injection, starting at 2.5 mg and titrating by 2.5 mg every four weeks until you reach a maintenance dose that works. The legal ceiling is 15 mg weekly ^[1][2]. That ladder is the same whether you take Mounjaro for type 2 diabetes or Zepbound for weight loss. What differs is the dose you settle on, how fast you climb, and what you do when side effects push back.

This page covers the full FDA titration schedule, indication-specific maintenance targets, missed dose rules, how to back off when GI symptoms get loud, special-population guidance from the label, and a complete mg-to-mL conversion chart for both brand pens and compounded vials.

The standard titration ladder

Tirzepatide ramps in six steps. Each step is a four-week minimum before the next bump. You do not have to advance on schedule. You do have to wait at least four weeks before moving up.

The 2.5 mg starting dose exists for tolerance, not efficacy. It builds tolerance to the slowed gastric emptying that drives most of the early nausea. Lilly designed the protocol around the SURPASS and SURMOUNT trial schedules, which both used a four-week initiation at 2.5 mg before moving to 5 mg ^[4][5].

Mounjaro versus Zepbound: same drug, different targets

Mounjaro and Zepbound are the same molecule at the same per-mg strength. The pens are identical in size and delivery. The difference is what you titrate toward.

Mounjaro (type 2 diabetes). You titrate to a glycemic target, usually an A1C under 7.0% or under 6.5% depending on your prescriber's plan. Many patients reach target at 10 mg and stay there. In SURPASS-2, 10 mg of tirzepatide reduced A1C by 2.0% on average, and the incremental drop from 10 mg to 15 mg was small (about 0.3%) ^[5]. If your blood sugar is controlled at 10 mg, there is no benefit to climbing further, and the side effect curve gets steeper.

Zepbound (weight loss). You titrate to a weight goal. Most patients land at 10 mg or 15 mg for maintenance. SURMOUNT-1 showed 15 mg produced the largest weight loss on average (about 20.9% of baseline body weight at 72 weeks), but the 10 mg arm also produced clinically meaningful loss (about 19.5%) ^[4]. The label does not require you to reach 15 mg. If 10 mg holds the weight off and the side effects are minimal, 10 mg is your maintenance.

How to handle a missed dose

The FDA labels for both Mounjaro and Zepbound use the same rule ^[1][2]:

• Within 4 days (96 hours) of the missed dose: take it as soon as you remember, then return to your normal weekly schedule.
• More than 4 days late: skip the missed dose. Take the next dose on your regularly scheduled day.

Do not double up. Two doses in the same week is not how you catch up, it is how you trigger severe nausea and vomiting. If you keep missing doses, talk to your prescriber about moving your injection day to one that sticks.

A related question: can you take tirzepatide a day early? Yes. The label allows changing your weekly injection day as long as the last dose was at least three days (72 hours) ago ^[1]. If you normally inject on Sunday and want to move to Friday, take your Friday dose, then your next dose the following Friday.

Adjusting for side effects

The most common reason people abandon tirzepatide is GI side effects. Nausea, vomiting, diarrhea, and constipation all spike during titration and usually fade within one to two weeks at a stable dose. The dose adjustments below are standard prescribing practice.

Slow the titration

If side effects flare every time you step up, stay at your current dose for an extra four to eight weeks before the next bump. The four-week rule is a minimum, not a maximum. Many endocrinologists keep patients at 5 mg or 7.5 mg for two to three months when GI tolerance is shaky.

Hold the step you are on

A four-week pause at the current dose lets the gut recalibrate. No rule says you must advance. People on 5 mg or 7.5 mg who feel fine and are seeing results have no clinical reason to push higher.

Drop back one step

If you escalated to a dose your body cannot tolerate after two to three weeks at that dose, drop back to the previous step. Six weeks later, try the higher dose again. The second attempt is usually better tolerated. This pattern shows up routinely in clinical practice and is supported by the label's "individualize" language ^[1][2].

Renal and hepatic adjustments

The FDA labels for both Mounjaro and Zepbound state that no dose adjustment is recommended for renal impairment, including end-stage renal disease, and no dose adjustment is recommended for hepatic impairment ^[1][2]. Tirzepatide is cleared primarily by proteolytic degradation, not by liver metabolism or kidney filtration in the conventional sense.

That said, the label does flag two real-world cautions:

• Acute kidney injury risk in patients who develop severe vomiting or diarrhea, particularly if also taking diuretics, ACE inhibitors, ARBs, or NSAIDs. Dehydration is the mechanism, not direct nephrotoxicity. Stay hydrated during titration.
• Limited experience in severe hepatic impairment. The pharmacokinetics did not change meaningfully, but clinical experience is thin.

Dialysis patients can take tirzepatide at standard doses ^[3]. There is no scheduling change tied to dialysis sessions.

Pediatric, pregnancy, and breastfeeding

Pediatric. Tirzepatide is not approved for use in anyone under 18 ^[1][2]. Safety and effectiveness have not been established in pediatric populations. Lilly has run pediatric obesity trials but no pediatric indication exists on the US label as of 2026.

Pregnancy. Tirzepatide is not recommended during pregnancy. The label advises discontinuing tirzepatide at least two months before a planned pregnancy because of the drug's long half-life and the lack of human pregnancy outcome data. Animal data showed fetal harm at clinically relevant exposures ^[2]. If you become pregnant unexpectedly while on tirzepatide, contact your prescriber promptly.

Breastfeeding. No data exist on whether tirzepatide is excreted in human milk. The decision to continue or stop should weigh the developmental and health benefits of breastfeeding against the mother's clinical need for the drug.

Drug interactions: insulin and sulfonylureas

Tirzepatide on its own causes very little hypoglycemia. The risk climbs sharply when it is combined with insulin or a sulfonylurea (glipizide, glyburide, glimepiride) because both classes drive insulin secretion or supply independent of glucose levels.

The standard adjustment is straightforward: reduce the insulin or sulfonylurea, not the tirzepatide ^[1]. A typical starting move is a 20% reduction in basal insulin or in sulfonylurea dose when tirzepatide is initiated, with further reductions as glucose readings drop. Tirzepatide is the agent doing the work; the older agent is the one creating the hypoglycemia risk.

Tirzepatide also slows gastric emptying, which can delay the absorption of oral medications. For most drugs this is irrelevant. For oral contraceptives specifically, the label recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose escalation ^[2]. Failed contraception on tirzepatide is a real reported event.

What happens after you stop

Tirzepatide's half-life is about five days ^[1]. That means it takes roughly four to five weeks after the last dose for the drug to fully clear your system. Appetite, gastric emptying, and insulin sensitivity all begin to revert during that window.

The post-discontinuation weight regain pattern is well documented. In the SURMOUNT-4 withdrawal trial, patients who switched from tirzepatide to placebo regained an average of about 14% of body weight over 52 weeks, while those who continued tirzepatide lost an additional 5.5%. The takeaway is not that the drug "stops working" but that the underlying obesity remains a chronic condition. The same is true for type 2 diabetes glycemic control: stopping tirzepatide returns A1C toward baseline within months.

A "wean off" taper is not required for safety. You will not experience withdrawal symptoms when stopping tirzepatide. Some prescribers recommend stepping down (from 15 mg to 10 mg to 5 mg over several months) to help patients learn to manage hunger at lower drug exposures before discontinuation, but this is a behavioral strategy, not a pharmacological one. Stopping cold turkey is medically safe.

Stopping and restarting

If you stop tirzepatide for more than four weeks and want to restart, the label recommends restarting at 2.5 mg and re-titrating from the beginning ^[1][2]. Your gut loses its tolerance to the gastric emptying effect after extended breaks. Jumping back in at your previous maintenance dose is the fastest way to vomit for three days.

Short interruptions of one to two weeks (a missed shipment, a vacation, a procedure) do not require re-titration. Resume at your previous dose. The boundary between "missed a dose" and "stopped the drug" is roughly four weeks, after which restarting at 2.5 mg becomes the safer default.

Complete dose chart: mg, mL, and units

The math behind tirzepatide volumes depends on whether you have a brand pen or a compounded vial. Brand pens deliver a fixed volume per push. Compounded vials require you to draw your dose with a U-100 insulin syringe based on the concentration printed on the label. For the full conversion math at a single dose, see How many mL is 2.5 mg of tirzepatide.

Brand pens (Mounjaro and Zepbound)

Each pen is single-dose and pre-filled at 0.5 mL ^[1][2]. The concentration changes with each pen strength so the volume stays constant.

Compounded vials at 5 mg/mL

This is the most common compounded concentration because it matches the 2.5 mg brand pen ratio.

Compounded vials at 10 mg/mL

Compounded vials at 20 mg/mL

Timing: day, time of day, and food

Tirzepatide is dosed once weekly on any day and at any time. The drug's five-day half-life means weekday and hour of day are clinically irrelevant for efficacy. Pick a day you will remember.

A few practical patterns from people who have run the full titration:

• Best day to inject. Many people pick Friday or Saturday so the peak side effect window (24 to 72 hours after the dose) falls on the weekend. If you work a demanding schedule, this matters more than the day itself.
• Best time of day. Morning is slightly more popular than evening, but no data supports either as superior. Taking tirzepatide at night is fine. Some people sleep through the early appetite suppression and find it helpful; others find nausea worse on an empty stomach overnight.
• Empty stomach or with food? Tirzepatide is subcutaneous, not oral, so food has no effect on absorption. Inject whenever fits your routine.

The drug peaks in the bloodstream around 24 hours after injection ^[1] and steady-state takes about four weeks of consistent weekly dosing to establish. That is why the four-week titration interval exists. It is also why you cannot judge a dose's tolerability from week one alone.

Microdosing tirzepatide

Microdosing tirzepatide refers to using doses below 2.5 mg, typically 0.5 to 2 mg weekly or split into smaller injections two to three times per week. It is not FDA approved, not studied in the SURPASS or SURMOUNT trials, and not supported by any prescribing label. The rationale, where it exists, is reducing GI side effects or extending vial supply.

A few facts worth knowing:

• Tirzepatide's half-life supports once-weekly dosing. Splitting into smaller, more frequent doses theoretically smooths peak-to-trough exposure but does not change total drug exposure.
• There is no clinical trial data on microdoses for weight loss, diabetes, fertility, or inflammation. Claims that microdoses help PCOS-related fertility or inflammatory conditions are not supported by published trial evidence.
• If your prescriber recommends a slower start (0.5 mg or 1 mg weekly) for GI tolerance before climbing to 2.5 mg, that is reasonable individual practice. It is not a standard protocol.

We have a dedicated article on the microdosing protocol math. The conversion is the same as the chart above, just substituted with smaller mg values.

Common questions about tirzepatide dosing

What is the maximum dose of tirzepatide?

15 mg once weekly is the maximum approved dose for both Mounjaro and Zepbound. Higher doses have not been studied in the trials that supported FDA approval.

How long does each step in the titration last?

Minimum four weeks per step. You can stay longer at any step if it is working or if side effects are not yet settled. You should not advance faster than every four weeks.

When should I increase my tirzepatide dose?

After at least four weeks at your current step, if side effects have settled and you are not yet at your glycemic or weight goal. If you are responding well and tolerating the current dose, there is no requirement to climb.

What happens if I skip a week of tirzepatide?

If you remember within four days, take the missed dose and resume the regular schedule. If more than four days have passed, skip it and take the next dose on schedule. Do not double up.

Can I split my tirzepatide dose into smaller injections?

There is no FDA-approved split-dose protocol. Some people split for side effect tolerance under prescriber guidance, but no trial data supports efficacy or safety of split dosing.

Does tirzepatide need to build up in your system?

Yes. Steady-state plasma concentration takes about four weeks of consistent weekly dosing. That is the pharmacokinetic reason behind the four-week titration interval.

What is the half-life of tirzepatide?

About five days. It takes roughly four to five weeks after the last dose for the drug to fully clear the body.

When does tirzepatide peak?

Plasma concentration peaks about 24 hours after subcutaneous injection. Side effects, especially nausea, typically peak 24 to 72 hours after the dose.

Can I take tirzepatide a day early?

Yes, as long as at least 72 hours have passed since the last injection. This is the standard way to change your weekly injection day.

Should I take tirzepatide on an empty stomach?

Tirzepatide is injected subcutaneously, not swallowed, so stomach contents do not affect absorption. Inject whenever fits your schedule.

Do I need to taper off tirzepatide?

No. Stopping cold turkey is medically safe. Weight regain or A1C rebound is common after discontinuation, but it is not a withdrawal effect, it is the underlying condition returning.

What dose do most people end up on for weight loss?

10 mg or 15 mg weekly. SURMOUNT-1 showed 15 mg produced the largest mean weight loss, but 10 mg also produced clinically meaningful results with fewer side effects.

What dose do most people end up on for type 2 diabetes?

10 mg weekly is the most common maintenance dose for glycemic control. Going to 15 mg adds only a small additional A1C reduction and raises the side effect rate.

Can pregnant women take tirzepatide?

No. Tirzepatide is not recommended during pregnancy. The label advises stopping at least two months before a planned pregnancy because of the drug's long half-life.

Is tirzepatide approved for children?

No. Tirzepatide is not approved for anyone under 18. Pediatric trials are underway but no indication exists on the current US label.

What this article does not cover

This page is the dosing and titration framework. Adjacent topics have dedicated articles on this site: the mg-to-mL conversion math for a specific starting dose, the full side effect profile, how tirzepatide compares with semaglutide head-to-head, and the cost differences between brand pens and compounded vials. The dosing rules above are constant across those topics. The brand, the pharmacy, and the price do not change the titration ladder.